Synexus lead the way with 52,000 DEXA scans in 10 months

26 Feb 2010

It took clinical trial experts Synexus, just ten months to carry out 52,000 DEXA scans and randomise over 2,700 patients across twelve of their UK, European and African dedicated research centres.

Commenting on the company's success recruiting patients for this Phase III osteoporosis trial for a top five pharma company chief executive Michael Fort said: "Once again our model has been shown to deliver the right numbers of patients at the right time even when it involves such a large scale logistical exercise. This was a complex late stage trial requiring mass screening of potential patients for randomization into the study. The company routinely screened over 1,000 patients a week for almost 12 months. Ultimately we were by far the largest clinical trials recruiter for this study, responsible for bringing in 23% of the patients in the global programme from less than 3% of the sites. All of our centres are equipped with state-of-the-art facilities including DEXA scanners. Our dedicated research centres, with full-time investigators are the way forward, helping us to recruit more quickly, and, in a big study, reducing set up and monitoring costs by millions of dollars."

Synexus, based in Manchester, is the world's largest multi-national company entirely focused on the recruitment and running of clinical trials at its own Dedicated Research Centres in the UK, Western, Central and Eastern Europe as well as South Africa and Asia. The company now has twenty six dedicated research centres, an increase of nine following its recent acquisition of German-based ClinPharm which has given Synexus a patient population reach of over 30 million patients; an increase of 50 per cent globally and 100 per cent across Europe.

The company has been successfully running large scale Phase III trials for a number of years, but believes that its recent acquisition, with such a significant increase in capacity across Central and Eastern Europe, will persuade more sponsors to cornerstone their Phase III trials with Synexus. Jeremy Hickling, Senior Vice President, Portfolio Management, is confident they will deliver first class results: "We can already demonstrate our capacity to handle tens of thousands of screenings in a very short space of time, now that we have expanded our operations, this is only going to improve."

Back to top ^

Synexus Limited, Registered in England and Wales, Registered number 3724238, Registered Office: Sandringham House, Ackhurst Park, Chorley , Lancashire, PR7 1NY

Strength in numbers

Synexus lead the way with 52,000 DEXA scans in 10 months

Regulatory

Patient

Therapy